Meridian extends into Taiwanese market:
This article was originally published in Clinica
Seoul, Korea-based manufacturer Meridian has signed a contract with Oliver, a Taiwanese medical equipment importer, for the exclusive national distribution of its Lapex 2000 LipoLaser. Oliver's licence is based on a minimum order volume equal to sales of $750,000 for an initial 12-month period. Oliver has pre-paid $100,000 for the first instalment of the initial purchase order. The Lapex 2000 is a noninvasive fat-reduction device that induces deep tissue warming to enhance microcirculation.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.